top
Search terms
Results 1 - 10 of 17 - ordered by :
Pages: 1 2
Ehjcvp

The Systolic Blood Pressure Intervention Trial (SPRINT) enrolled 9300 participants age 50 years and older without diabetes or previous stroke in 100 expert medical centres and clinical practices ...

European Heart Journal - Cardiovascular Pharmacotherapy, INVITED EDITORIAL, Sverre E. Kjeldsen, Giuseppe Mancia

Date : 01/04/2016 Item size : 128053 bytes
Ehjcvp

Hypertension constitutes a major risk factor for cardiovascular mortality, myocardial infarction, heart failure, stroke, atrial fibrillation, and peripheral arterial disease, with one billion people ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEW, Vasiliki Katsi, Georgios Skalis, Antonis N. Pavlidis, Thomas Makris, Petros Nihoyannopoulos, Dimitris Tousoulis, Ioannis Kallikazaros

Date : 01/10/2015 Item size : 268677 bytes
Ehjcvp

Optimization of heart failure medication after cardiac resynchronization therapy and the impact on long-term survival Abstract Aims Treatment with evidence-based heart failure (HF) medication ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLE, Christoffer Tobias Witt, Mads Brix Kronborg, Ellen Aagaard Nohr, Peter Thomas Mortensen, Christian Gerdes, Jens Cosedis ...

Date : 01/07/2015 Item size : 273569 bytes
Ehjcvp

In a meta-analysis, in this issue of the journal, Kuljit Singh and co-workers from the University of Ottawa Heart Institute in Canada report that despite rapid revascularization and treatment of ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIAL, Stefan Agewall

Date : 01/10/2015 Item size : 96385 bytes
Ehjcvp

Optimal handling of the healthy In the preventive section, the HOPE-3 (Heart Outcomes Prevention Evaluation 3) trial stole the limelight, first and foremost by strengthening faith in statinsthis time ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIALS, Manan Pareek, Deepak L. Bhatt

Date : 01/07/2016 Item size : 164372 bytes
Ehjcvp

[...]SGLT2 inhibition represents a novel treatment, which might be a promising target not only to (further) reduce blood glucose but also to target other cardiovascular risk factors. SGLT2 ...

European Heart Journal - Cardiovascular Pharmacotherapy, Review, Anne E. de Leeuw, Rudolf A. de Boer

Date : 01/10/2016 Item size : 586778 bytes
Ehjcvp

Introduction Non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) have been used in clinical practice for more than a century and are among the most widely used drugs worldwide for the ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEWS, Morten Schmidt, Morten Lamberts, Anne-Marie Schjerning Olsen, Emil Fosbøll, Alexander Niessner, Juan Tamargo, Giuseppe Rosano, ...

Date : 01/04/2016 Item size : 461588 bytes
Ehjcvp

[...]SGLT2 inhibition represents a novel treatment, which might be a promising target not only to (further) reduce blood glucose but also to target other cardiovascular risk factors. SGLT2 ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEW, Anne E. de Leeuw, Rudolf A. de Boer

Date : 18/04/2016 Item size : 590679 bytes
Ehjcvp

Abstract Renal sympathetic denervation (RDN) has been proposed as a new treatment modality in patients with apparent treatment-resistant hypertension (TRH), a condition defined as persistent blood ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEW, Sverre E. Kjeldsen, Fadl Elmula M. Fadl Elmula, Ingrid Os, Alexandre Persu, Yu Jin, Jan A. Staessen

Date : 01/01/2015 Item size : 349851 bytes
Ehjcvp

Abstract Cardiovascular disease is the leading cause of morbidity and mortality among patients with diabetes, underscoring the importance of choosing anti-diabetic drugs that do not increase ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEWS, R. Kumar, D. M. Kerins, T. Walther

Date : 01/01/2016 Item size : 517106 bytes